Mein Warenkorb

SSTR2

SSTR2 Molekülinformation

Englischer NameSomatostatin receptor 2Anzahl der inverkehr gebrachten Arzneimittel6
Anzahl der klinischen Arzneimittel18Target-AliasSomatostatin receptor type 2,SS-2-R,SS2R,SSTR2,Somatostatin Receptor 2,SRIF-1,SS2-R
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameSomatostatin receptor 2
Target-AliasSomatostatin receptor type 2,SS-2-R,SS2R,SSTR2,Somatostatin Receptor 2,SRIF-1,SS2-R
Anzahl der inverkehr gebrachten Arzneimittel6
Anzahl der klinischen Arzneimittel18
Höchste Forschungs- und EntwicklungsphaseApproved

SSTR2 Produktliste

  • Attribut

    Protein (2)Cell (1)

  • Produktbibliothek

    Online (3)

  • Spezies

    Human (3)

  • Etikett

    - (2)GFP Tag (1)

  • Marker

    Unconjugated (1)GFP Fusion (1)- (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
CHEK-ATP213
Human
HEK293
HEK293/Human SSTR2 Stable Cell Line In den Warenkorb legen
SS2-H5216
Human
HEK293
Human SSTR2 Full Length Protein (VLP) In den Warenkorb legen
SS2-HF2G3
Human
HEK293
Fluorescent Human SSTR2 Full Length Protein (VLP) In den Warenkorb legen
Gesamtmenge3
  • 1

SSTR2 Molekülhintergrund

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family and have a wide expression pattern in both normal tissues and solid tumors. Investigating the function of each SSTR in several tumor types has provided a wealth of information about the common but also distinct signaling cascades that suppress tumor cell proliferation, survival and angiogenesis. This provided the rationale for developing multireceptor-targeted somatostatin analogs and combination therapies with signaling-targeted agents such as inhibitors of the mammalian (or mechanistic) target of rapamycin (mTOR). The ability of SSTR to internalize and the development of rabiolabeled somatostatin analogs have improved the diagnosis and treatment of neuroendocrine tumors.

SSTR2 Molekülalias

Smstr2,Somatostatin R2,somatostatin receptor 2,somatostatin receptor type 2,SomatostatinR2,SRIF-1,SS2R,SS-2-R,SS2-R,SST2,SSTR2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
PaltusotineCRN-00808Phase 3 ClinicalCrinetics Pharmaceuticals IncAcromegaly; Malignant Carcinoid Syndrome; Neuroendocrine Tumors
Details
Lutetium-177 labelled edotreotideITM-11Phase 3 ClinicalUniversitaetsspitals Basel, Itm Solucin GmbhSolid tumours; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Central Nervous System Neoplasms; Thymus Neoplasms; Carcinoma, Neuroendocrine; Lung Neoplasms; Lymphoma; Gastroenteropancreatic neuroendocrine tumor
Details
Actinium-225 DotateRYZ-101; 225Ac-DOTATATEPhase 3 ClinicalRayzeBio IncCarcinoid Tumor; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Metastatic breast cancer; Gastroenteropancreatic neuroendocrine tumor
Details
Lutetium-177 DOTA satoreotide[177Lu]LuSSO110; 177Lu-DOTA- JR11; 177Lu-satoreotide; 177Lu-IPN01072; 177Lu-IPN-1072; 177Lu SSO 110; OPS-201; 177LU-OPS 201Phase 2 ClinicalOctreoPharm Sciences GmbHSmall Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Breast Neoplasms; Meningioma
Details
Nendratareotide uzatansineBTP-277; PEN-221Phase 2 ClinicalTarveda Therapeutics IncSmall Cell Lung Carcinoma; Neuroendocrine Tumors; Carcinoma, Neuroendocrine
Details
Yttrium 90-labelled edotreotideSMT-487-[90Y]; DOTATOC-[90Y]Phase 2 ClinicalThe University Of Iowa, Novartis Pharma AgSolid tumours; Medulloblastoma; Skin Melanoma; Pheochromocytoma; Carcinoid Tumor; Adenoma, Islet Cell; Neoplasms; Central Nervous System Neoplasms; Neuroendocrine Tumors; Neuroblastoma; Breast Neoplasms; Sarcoma; Brain Neoplasms; Lymphoma; Lung Neoplasms; Meningioma
Details
ZT-01ZT 01; ZT-01Phase 2 ClinicalTulane University, York University, University Of Toronto, TorontoDiabetes Mellitus, Type 1; Hypoglycemia
Details
Re-188 P 2045P2045; BAY-865284; Rhenium-188 P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188-P-2045Phase 2 ClinicalBayer AGNeoplasm Recurrence, Local; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung
Details
MB-0151Phase 2 ClinicalMainline Biosciences (Shanghai) Co Ltd, Zhongshan Zhuliuyuan Biotechnology Co LtdSolid tumours
Details
177Lu-LNC1010177Lu-LNC1010Phase 2 ClinicalYantai Lanna Cheng Biotechnology Co LtdSolid tumours; Neoplasms; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors
Details
[203-Pb] VMT-NET[203-Pb] VMT-NETPhase 2 ClinicalPerspective Therapeutics IncHead and Neck Neoplasms; Pheochromocytoma; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Paraganglioma
Details
64Cu-SarTatePhase 2 ClinicalClarity Pharmaceuticals Ltd, University Of MelbourneNeuroendocrine Tumors; Neuroblastoma; Meningioma
Details
68Ga-NOTA-3PTATE-RGD68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGDPhase 1 ClinicalPeking Union Medical College HospitalNeuroendocrine Tumors; Lung Neoplasms; Meningioma
Details
[225Ac]Ac-DOTATATEPhase 1 ClinicalBeijing Xiantong International Technology Co LtdNeuroendocrine Tumors
Details
[99mTc]Tc-TECANT1Phase 1 ClinicalLjubljana University Medical Centre, Medical University Of Innsbruck, Narodowe Centrum Badan Jadrowych, Jagiellonian University Sylff Fellows AssociationNeuroendocrine Tumors
Details
161Tb-DOTA-LM3161Tb-DOTA-LM3Phase 1 ClinicalUniversity Hospital BaselNeuroendocrine Tumors; Gastroenteropancreatic neuroendocrine tumor
Details
44Sc-edotreotide44Sc-edotreotide; 44Sc-DOTA-[3-Tyr]-octreotide; Sc44-DOTATOCClinicalZentralklinik Bad BerkaDiagnostic agents
Details
225AcDOTA-LM3225AcDOTA-LM3ClinicalCURANOSTICUM Wiesbaden-FrankfurtPancreatic neuroendocrine tumors (pNET)
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pasireotide PamoateApprovedNovartis Pharma AgSignifor larUnited StatesAcromegalyRecordati Rare Diseases Inc2014-12-15Acromegaly; Gigantism; Cushing Syndrome; Carcinoid Tumor; Neuroendocrine Tumors; Pituitary ACTH Hypersecretion; Meningioma
Details
Lutetium (177Lu) oxodotreotideLu-DOTATATE; Lutetium (177Lu) DOTA-TATE; 177Lu-DOTATATE; [Lu-177]-DOTATATE; AAA-601; F-1515; XTR-008; [177Lu]Lu-DOTA-TATEApprovedAdvanced Accelerator Applications SaLutatheraEUNeuroendocrine TumorsAdvanced Accelerator Applications Sa2017-09-26Prostatic Neoplasms; Carcinoid Heart Disease; Meningioma; Gastroenteropancreatic neuroendocrine tumor; Paraganglioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Lung Neoplasms; Pituitary Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); Neuroblastoma; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Adenoma, Islet Cell; Malignant Carcinoid Syndrome; Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Bronchial Neoplasms; Carcinoid Tumor; Pheochromocytoma; Leiomyosarcoma
Details
Vapreotide AcetateRC-160; BMY-41606ApprovedDebiopharm GroupSanvar, Docrised, Sanvar IR, Sanvar SRAcromegaly; Pancreatic Neoplasms; Hypertension, Portal; Neuroendocrine Tumors; Hemorrhage; Diarrhea; Intraoperative Complications; Postoperative Complications; Esophageal and Gastric Varices; Crohn Disease
Details
Pasireotide DiaspartateSOM-230; SOM-230C; SOM-320ApprovedNovartis Pharma AgSignifor, 丝尼芬EUCushing SyndromeRecordati Rare Diseases Inc2012-04-24Thyroid Neoplasms; Uveal melanoma; Multiple Myeloma; Prostatic Neoplasms; Medullary thyroid cancer (MTC); Alcoholism; Nelson Syndrome; Pituitary Neoplasms; Hyperinsulinism; Cysts; Thymoma; Cluster Headache; Gastroenteropancreatic neuroendocrine tumor; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Prolactinoma; Meningioma; Post-bariatric Hypoglycemia; Liver Cirrhosis; ACTH Syndrome, Ectopic; Congenital Hyperinsulinism; Cushing Syndrome; Dumping Syndrome; Carcinoid Tumor; Renal Insufficiency; Insulinoma; Pancreatic Neoplasms; Acromegaly; Neoplasms; Hormone-Resistant Prostate Neoplasms; Hypoglycemia; Small Cell Lung Carcinoma; Adenoma, Islet Cell; Pituitary ACTH Hypersecretion; Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant
Details
Ga-68 EdotreotideSMT-487; [68Ga]DOTATOC; 90Y-DOTATOCApprovedAdvanced Accelerator Applications SaSomaKit TOC, Gallium Dotatoc Ga 68, TOCscanEUDiagnostic agents; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine TumorsAdvanced Accelerator Applications Sa2016-12-08Medulloblastoma; Multiple Endocrine Neoplasia Type 1; Carcinoid Tumor; Pancreatic neuroendocrine tumors (pNET); Neuroendocrine Tumors; Neuroblastoma; Pituitary Neoplasms; Diagnostic agents; Paraganglioma; Meningioma; von Hippel-Lindau Disease; Somatostatinoma
Details
Gallium (68Ga) oxodotreotide68Ga-DOTA-TATE; 68-Ga-DOTA-TATE; AAA-501ApprovedAdvanced Accelerator Applications SaNetspotUnited StatesNeuroendocrine TumorsAaa Usa Inc2016-06-01Pheochromocytoma; Carcinoid Tumor; Pancreatic Neoplasms; Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Neuroendocrine; Thyroid Neoplasms; Paraganglioma; von Hippel-Lindau Disease; Carcinoma, Hepatocellular
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns